Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Foghorn Therapeutics Inc (FHTX)

Foghorn Therapeutics Inc (FHTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 285,618
  • Shares Outstanding, K 42,566
  • Annual Sales, $ 34,160 K
  • Annual Income, $ -98,430 K
  • 60-Month Beta 3.17
  • Price/Sales 7.83
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade FHTX with:

Options Overview Details

View History
  • Implied Volatility 92.96% ( -13.51%)
  • Historical Volatility 109.15%
  • IV Percentile 64%
  • IV Rank 22.95%
  • IV High 273.21% on 10/26/23
  • IV Low 39.26% on 01/22/24
  • Put/Call Vol Ratio 0.25
  • Today's Volume 69
  • Volume Avg (30-Day) 27
  • Put/Call OI Ratio 0.02
  • Today's Open Interest 539
  • Open Int (30-Day) 848

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -0.55
  • Number of Estimates 3
  • High Estimate -0.51
  • Low Estimate -0.59
  • Prior Year -0.73
  • Growth Rate Est. (year over year) +24.66%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.78 +16.06%
on 03/15/24
8.44 -20.50%
on 03/01/24
-1.07 (-13.75%)
since 02/28/24
3-Month
2.70 +148.52%
on 02/05/24
8.44 -20.50%
on 03/01/24
-0.05 (-0.74%)
since 12/28/23
52-Week
2.70 +148.52%
on 02/05/24
9.97 -32.70%
on 08/15/23
+1.00 (+17.51%)
since 03/28/23

Most Recent Stories

More News
Flagship Pioneering Announces the Merger of Two Leading Programmable Medicine Platforms to Form Sail Biomedicines

/PRNewswire/ -- Flagship Pioneering today announced the combination of Laronde and Senda Biosciences to launch Sail Biomedicines, a company pioneering the...

DNLI : 20.52 (-1.20%)
FHTX : 6.71 (+6.85%)
MRNA : 106.56 (-3.64%)
OMGA : 3.65 (+2.82%)
SANA : 10.00 (unch)
MCRB : 0.7741 (-0.78%)
Flagship Pioneering Appoints John Lepore as CEO-Partner and CEO of ProFound Therapeutics

/PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and ProFoundâ„¢ Therapeutics, a company pioneering the discovery of a vastly expanded...

DNLI : 20.52 (-1.20%)
FHTX : 6.71 (+6.85%)
MRNA : 106.56 (-3.64%)
OMGA : 3.65 (+2.82%)
SANA : 10.00 (unch)
MCRB : 0.7741 (-0.78%)
Flagship Pioneering Named to Fortune's 2023 "Change the World" List

/PRNewswire/ -- Flagship Pioneering today announced it has been named to FORTUNE's 2023 "Change the World" list, an annual global ranking of companies that...

DNLI : 20.52 (-1.20%)
FHTX : 6.71 (+6.85%)
MRNA : 106.56 (-3.64%)
OMGA : 3.65 (+2.82%)
SANA : 10.00 (unch)
MCRB : 0.7741 (-0.78%)
Flagship Pioneering Announces Appointment of Amanda Kay as Chief Business Development Officer

/PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, announced today the appointment of Amanda Kay as Senior Partner and Chief Business...

DNLI : 20.52 (-1.20%)
FHTX : 6.71 (+6.85%)
MRNA : 106.56 (-3.64%)
OMGA : 3.65 (+2.82%)
SANA : 10.00 (unch)
MCRB : 0.7741 (-0.78%)
Flagship Pioneering Announces Appointment of David Khougazian as Growth Partner

/PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, announced today that pharma and healthcare leader David Khougazian is joining as...

DNLI : 20.52 (-1.20%)
FHTX : 6.71 (+6.85%)
MRNA : 106.56 (-3.64%)
OMGA : 3.65 (+2.82%)
SANA : 10.00 (unch)
MCRB : 0.7741 (-0.78%)
Flagship Pioneering Appoints Jason Gardner as CEO-Partner and CEO of Ampersand Biomedicines

/PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and Ampersand Biomedicines, a company programming smarter medicines that act...

DNLI : 20.52 (-1.20%)
FHTX : 6.71 (+6.85%)
MRNA : 106.56 (-3.64%)
OMGA : 3.65 (+2.82%)
SANA : 10.00 (unch)
MCRB : 0.7741 (-0.78%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Foghorn Therapeutics Inc. - FHTX

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Foghorn Therapeutics Inc. ("Foghorn" or the "Company") (NASDAQ: FHTX). Such...

FHTX : 6.71 (+6.85%)
Foghorn Therapeutics Inc. (FHTX) Reports Q1 Loss, Lags Revenue Estimates

Foghorn Therapeutics Inc. (FHTX) delivered earnings and revenue surprises of -7.35% and 12.88%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?...

FHTX : 6.71 (+6.85%)
PRPH : 6.47 (+3.35%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Foghorn Therapeutics Inc. - FHTX

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Foghorn Therapeutics Inc. ("Foghorn" or the "Company") (NASDAQ: FHTX). Such...

FHTX : 6.71 (+6.85%)
Foghorn Therapeutics Inc. (FHTX) Soars 13.1%: Is Further Upside Left in the Stock?

Foghorn Therapeutics Inc. (FHTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength...

FHTX : 6.71 (+6.85%)
ACRS : 1.2400 (-1.59%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Strengthening short term outlook on maintaining the current direction.

See More Share

Business Summary

Foghorn Therapeutics Inc. engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system. Foghorn Therapeutics Inc. is based in CAMBRIDGE, Mass.

See More

Key Turning Points

3rd Resistance Point 7.39
2nd Resistance Point 7.08
1st Resistance Point 6.89
Last Price 6.71
1st Support Level 6.39
2nd Support Level 6.08
3rd Support Level 5.89

See More

52-Week High 9.97
Fibonacci 61.8% 7.19
Last Price 6.71
Fibonacci 50% 6.34
Fibonacci 38.2% 5.48
52-Week Low 2.70

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar